코오롱생명과학

102940KOSDAQ기초 의약물질 제조업

55.6 / 100

Reference Date: 2026-06-10

Financial Score20.0 / 40

News Sentiment19.6 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 22.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Kolon Life Science operates three business segments: Chemical, SC, and Bio. The Chemical segment, focused on pharmaceutical API production, drives revenue growth due to expanding global pharmaceutical markets and increased outsourcing of raw material production. However, the Bio segment continues to report significant losses.

Number of Employees

454people

Average Salary

60.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

25.07Industry Average 27.715.0Point

In line with industry avg

PBR

1.07Industry Average 1.745.5Point

Lower than industry avg (good)

ROE

6.81Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

27.50Industry Average 6.620.0Point

4.2x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲29.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲94.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -26.1% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 78.3

Positive
코오롱베니트, '제조DX컨설팅팀' 신설…제조 DX·AX 전환 전담
코오롱생명과학 자회사 코오롱베니트의 제조DX 컨설팅팀 신설로 디지털 전환 지원 강화, 관련 사업 확대 기대.
Positive
코오롱생명과학, 美서 항암 유전자치료제 전임상 발표
코오롱생명과학의 항암 유전자치료제 KLS-3021이 TNBC에 대한 긍정적인 전임상 결과를 미국 학회에서 발표하며 주가 상승 기대.
Positive
코오롱생명과학, 코오롱바이오텍에 150억 현금출자 결정
코오롱생명과학의 코오롱바이오텍에 대한 현금출자 결정으로 유동성 강화 기대.

Detailed Momentum

52-week position5.0Point

52w mid range (45%)

Current 47,800Won52-week high 70,80052-week low 28,400

1-month return0.0Point

1m -22.02% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-05-29
Neutral특수관계인에대한출자2026-05-18
Neutral분기보고서 (2026.03)2026-05-15